ES2206955T3 - Inhibidores de metaloproteinasas, su empleo terapeutico y procedimiento para la produccion del compuesto de partida en su sintesis. - Google Patents

Inhibidores de metaloproteinasas, su empleo terapeutico y procedimiento para la produccion del compuesto de partida en su sintesis.

Info

Publication number
ES2206955T3
ES2206955T3 ES98932516T ES98932516T ES2206955T3 ES 2206955 T3 ES2206955 T3 ES 2206955T3 ES 98932516 T ES98932516 T ES 98932516T ES 98932516 T ES98932516 T ES 98932516T ES 2206955 T3 ES2206955 T3 ES 2206955T3
Authority
ES
Spain
Prior art keywords
compound
compounds
mmol
zinc
metalloproteinases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98932516T
Other languages
English (en)
Spanish (es)
Inventor
Vincenzo Politi
Enrico Gavuzzo
Carlo Gallina
Giovanni Di Stazio
Silvana D'alessio
Antonio Sella
Cinzia Piazza
Cesare Giordano
Barbara Gorini
Gabriella Panini
Mario Paglialunga Paradisi
Maurizio Cirilli
Giorgio Pochetti
Fernando Mazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polifarma SpA
Consiglio Nazionale delle Richerche
Original Assignee
Polifarma SpA
Consiglio Nazionale delle Richerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polifarma SpA, Consiglio Nazionale delle Richerche filed Critical Polifarma SpA
Application granted granted Critical
Publication of ES2206955T3 publication Critical patent/ES2206955T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES98932516T 1997-07-17 1998-07-17 Inhibidores de metaloproteinasas, su empleo terapeutico y procedimiento para la produccion del compuesto de partida en su sintesis. Expired - Lifetime ES2206955T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM970441 1997-07-17
IT97RM000441A IT1296305B1 (it) 1997-07-17 1997-07-17 Inibitori di metalloproteinasi loro uso terapeutico e procedimento per la produzione del composto di partenza nella loro

Publications (1)

Publication Number Publication Date
ES2206955T3 true ES2206955T3 (es) 2004-05-16

Family

ID=11405183

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98932516T Expired - Lifetime ES2206955T3 (es) 1997-07-17 1998-07-17 Inhibidores de metaloproteinasas, su empleo terapeutico y procedimiento para la produccion del compuesto de partida en su sintesis.

Country Status (8)

Country Link
US (1) US6339160B1 (enExample)
EP (1) EP1019434B1 (enExample)
JP (1) JP3325017B2 (enExample)
AU (1) AU8241898A (enExample)
DE (1) DE69818698T2 (enExample)
ES (1) ES2206955T3 (enExample)
IT (1) IT1296305B1 (enExample)
WO (1) WO1999003878A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6683165B1 (en) 1999-04-13 2004-01-27 Genome Therapeutics Corporation Human gene relating to respiratory diseases and obesity
GB9922577D0 (en) * 1999-09-23 1999-11-24 Center For Clinical & Basic Re Substituted phosphinate based peptide derivatives
WO2001078894A2 (en) * 2000-04-13 2001-10-25 Schering Corporation Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
US7364719B2 (en) * 2002-10-04 2008-04-29 The United States Of America As Represented By The Department Of Health And Human Services Vasoregulating compounds and methods of their use
AU2003295422B2 (en) * 2002-11-07 2009-01-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A new target for angiogenesis and anti-angiogenesis therapy
BRPI0400284A (pt) * 2004-03-18 2005-11-01 Fundacao Oswaldo Cruz Uso de dm 43 e seus fragmentos como inibidor de metaloproteases de matriz
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
GB0708507D0 (en) * 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
EP3860608A1 (en) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0401963A1 (en) 1989-04-13 1990-12-12 Beecham Group p.l.c. Phosphonopeptides with collagenase inhibiting activity
IT1242002B (it) * 1990-10-03 1994-02-02 Polifarma Spa Composti con attivita' farmacologica antiipertensiva, analgesica, immunomodulante e antiinfiammatoria, che presentano nella molecola una sequenza di tre radicali, essendo alfa-amminoacido quello centrale
IT1277904B1 (it) * 1995-08-07 1997-11-12 Polifarma Spa Metodo per determinare l'attivita' terapeutica di composti inibitori di metalloproteinasi, nuovi composti inibitori, e loro impiego

Also Published As

Publication number Publication date
IT1296305B1 (it) 1999-06-25
AU8241898A (en) 1999-02-10
ITRM970441A0 (enExample) 1997-07-17
ITRM970441A1 (it) 1999-01-17
EP1019434B1 (en) 2003-10-01
WO1999003878A3 (en) 1999-04-01
JP3325017B2 (ja) 2002-09-17
WO1999003878A2 (en) 1999-01-28
JP2001525315A (ja) 2001-12-11
DE69818698D1 (de) 2003-11-06
DE69818698T2 (de) 2004-08-19
US6339160B1 (en) 2002-01-15
EP1019434A2 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
ES2226482T3 (es) Inhibidores de trombina.
ES2327819T3 (es) Imidazolidinonas como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
FR2609289A1 (fr) Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
JPH09511501A (ja) ２６ｓタンパク質分解複合体とその中に含まれる２０ｓプロテアソームの阻害剤
ES2208898T3 (es) Supresion de la respuesta inmune a traves de la inhibicion de la catepsina s.
WO1998049190A2 (en) Substituted oxadiazole cysteine protease inhibitors
CA2096225A1 (en) Matrix metalloprotease inhibitors
JPH05504775A (ja) トロンビンの阻害剤および基質
PT101027A (pt) Peptideos, processo para a sua preparacao e sua utilizacao como compostos farmaceuticos
EP0480044A1 (en) Novel 4h-3,1-benzoxazin-4-one derivative
EP1019434B1 (en) Inhibitors of metalloproteinases, their therapeutic use, and process for the production of the starting compound in their synthesis
ES2304639T3 (es) Nuevos derivados del 2-hidroxitetrahidrofurano y su aplicacion como medicamentos.
US5679700A (en) Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
PL177661B1 (pl) Inhibitor metaloproteaz substancji międzykomórkowej i kompozycja farmaceutyczna
ES2264134T3 (es) Metodo para la determinacion de la actividad terapeutica de compuestos inhibidores de metaloproteinasas, compuestos inhibidores nuevos y el uso terapeutico de los mismos.
PT92554A (pt) Processo para a preparacao de peptideos inibidores de protease retroviral
ES2244969T3 (es) Inhibidores de la tripeptidilpeptidasa.
AU713863B2 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
SU1272982A3 (ru) Способ получени производных пролина или их фармацевтически приемлемых солей
JPH11514378A (ja) トロンビン阻害剤
PT97782A (pt) Processo para a preparacao de peptideos inibidores da protease do hiv
EP0159396B1 (en) Carboxyalkyl peptide derivatives
CA2227607C (en) Penicillaminamide derivatives
RU2840908C2 (ru) Ингибитор основной протеазы коронавируса SARS-CoV-2
SU1660578A3 (ru) Способ получени N-[3-(N-циклопентакарбонил-D-аланилтио)-2-D-метилпропаноил]-L-пролина